Heritability of magnetic resonance imaging (MRI) traits in Alzheimer disease cases and their siblings in the MIRAGE study

Alzheimer Disease and Associated Disorders

Volumn 21, Issue 2, 2007, Pages 85-91

  Lunetta, Kathryn L ^a   Erlich, Porat M ^b   Cuenco, Karen T ^b   Adrienne Cupples, L ^a   Green, Robert C ^a,b   Farrer, Lindsay A ^a,b   DeCarli, Charles ^c  

^a BOSTON UNIVERSITY   (United States)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Alzheimer disease; APOE; Heritability; Magnetic resonance imaging

Indexed keywords

APOLIPOPROTEIN E4;

AGED; ALZHEIMER DISEASE; ARTICLE; BRAIN ATROPHY; BRAIN CORTEX; CEREBROVASCULAR DISEASE; CONTROLLED STUDY; COVARIANCE; FEMALE; GENE MUTATION; GENETIC EPIDEMIOLOGY; GENOTYPE; HERITABILITY; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RESEARCH; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PHENOTYPE; PRIORITY JOURNAL; SIBLING; TEMPORAL LOBE; TWIN DISCORDANCE; WHITE MATTER;

ALZHEIMER DISEASE; APOLIPOPROTEIN E4; BRAIN; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; PEDIGREE; QUANTITATIVE TRAIT, HERITABLE; SIBLINGS;

EID: 34249938433     PISSN: 08930341     EISSN: None     Source Type: Journal    
DOI: 10.1097/WAD.0b013e3180653bf7     Document Type: Article

References (63)

1. Farrer LA, Cupples LA, Haines JL, et al. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. JAMA. 1997;278:1349-1356.
2. Nalbantoglu J, Gilfix BM, Bertrand P, et al. Predictive value of apolipoprotein E genotyping in Alzheimer's disease: results of an autopsy series and an analysis of several combined studies. Ann Neurol. 1994;36:889-895.
3. Roses AD, Devlin B, Conneally PM, et al. Measuring the genetic contribution of APOE in late-onset Alzheimer disease (AD). Am J Hum Genet. 1995;57:A202.
4. Kennedy JL, Farrer LA, Andreasen NC, et al. The genetics of adult-onset neuropsychiatric disease: complexities and conundra? Science. 2003;302:822-826.
5. Seab JP, Jagust WJ, Wong STS, et al. Quantitative NMR measurements of hippocampal atrophy in Alzheimer's disease. Magn Resonance Med. 1988;8:200-208.
6. Jack CR, Petersen RC, O'Brien PC, et al. MR-based hippocampal volumetry in the diagnosis of Alzheimer's disease. Neurology. 1992;42:183-188.
7. DeCarli C, Murphy DG, McIntosh AR, et al. Discriminant analysis of MRI measures as a method to determine the presence of dementia of the Alzheimer type. Psychiatry Res. 1995;57:119-130.
8. Jack CR Jr, Petersen RC, Xu YC, et al. Medial temporal atrophy on MRI in normal aging and very mild Alzheimer's disease (see comments). Neurology. 1997;49:786-794.
9. Petersen RC, Jack CR Jr, Xu YC, et al. Memory and MRI-based hippocampal volumes in aging and AD. Neurology. 2000;54:581-587.
10. de Leon MJ, Convit A, Tarshish C, et al. MRI studies of the hippocampal formation: contributions to the early diagnosis of Alzheimer's disease. In: de Leon M, ed. An Atlas of Alzheimer's Disease. New York: The Partheon Publishing Group; 1999.
11. Jack CR, Dickson DW, Parisi JE, et al. Antemortem MRI findings correlate with hippocampal neuropathology in typical aging and dementia. Neurology. 2002;58:750-757.
12. Killiany RJ, Gomez-Isla T, Moss M, et al. Use of structural magnetic resonance imaging to predict who will get Alzheimer's disease (see comments). Ann Neurol. 2000;47:430-439.
13. Fox NC, Freeborough PA, Rossor MN. Visualisation and quantification of rates of atrophy in Alzheimer's disease (see comments). Lancet. 1996;348:94-97.
14. Fox NC, Freeborough PA. Brain atrophy progression measured from registered serial MRI: validation and application to Alzheimer's disease. J Magn Resonance Imaging. 1997;7:1069-1075.
15. Freeborough PA, Fox NC. The boundary shift integral: an accurate and robust measure of cerebral volume changes from registered repeat MRI. IEEE Transact Med Imaging. 1997;16:623-629.
16. Fox NC, Warrington EK, Rossor MN. Serial magnetic resonance imaging of cerebral atrophy in preclinical Alzheimer's disease (letter). Lancet. 1999;353:2125.
17. Jack CR Jr, Petersen RC, Xu Y, et al. Rates of hippocampal atrophy correlate with change in clinical status in aging and AD. Neurology. 2000;55:484-489.
18. Fox NC, Scahill RI, Crum WR, et al. Correlation between rates of brain atrophy and cognitive decline in AD (see comments). Neurology. 1999;52:1687-1689.
19. Jack CR Jr, Shiung MM, Gunter JL, et al. Comparison of different MRI brain atrophy rate measures with clinical disease progression in AD. Neurology. 2004;62:591-600.
20. Jack CR Jr, Shiung MM, Weigand SD, et al. Brain atrophy rates predict subsequent clinical conversion in normal elderly and amnestic MCI. Neurology. 2005;65:1227-1231.
21. Wolf PA, D'Agostino RB, Belanger AJ, et al. Probability of stroke: a risk profile from the Framingham Study. Stroke. 1991;22:312-318.
22. Longstreth WT Jr, Bernick C, Manolio TA, et al. Lacunar infarcts defined by magnetic resonance imaging of 3660 elderly people: the Cardiovascular Health Study. Arch Neurol. 1998;55:1217-1225.
23. Manolio TA, Kronmal RA, Burke Gl, et al. Magnetic resonance abnormalities and cardiovascular disease in older adults: the Cardiovascular Health Study. Stroke. 1994;25:318-327.
24. Decarli C, Massaro J, Harvey D, et al. Measures of brain morphology and infarction in the Framingham heart study: establishing what is normal. Neurobiol Aging. 2005;26:491-510.
25. Wu CC, Mungas D, Petkov CI, et al. Brain structure and cognition in a community sample of elderly Latinos. Neurology. 2002;59:383-391.
26. Slooter AJ, van Duijn CM, Bots ML, et al. Apolipoprotein E genotype, atherosclerosis, and cognitive decline: the Rotterdam Study. J Neural Transm Suppl. 1998;53:17-29.
27. Launer LJ, Ross GW, Petrovitch H, et al. Midlife blood pressure and dementia: the Honolulu-Asia aging study. Neurobiol Aging. 2000;21:49-55.
28. Skoog I, Lernfelt B, Landahl S, et al. 15-year longitudinal study of blood pressure and dementia. Lancet. 1996;347:1141-1145.
29. Kivipelto M, Helkala EL, Hanninen T, et al. Midlife vascular risk factors and late-life mild cognitive impairment: a population-based study. Neurology. 2001;56:1683-1689.
30. Kivipelto M, Helkala EL, Laakso MP, et al. Midlife vascular risk factors and Alzheimer's disease in later life: longitudinal, population based study. BMJ. 2001;322:1447-1451.
31. Kivipelto M, Laakso MP, Tuomilehto J, et al. Hypertension and hypercholesterolaemia as risk factors for Alzheimer's disease: potential for pharmacological intervention. CNS Drugs. 2002;16:435-444.
32. Seshadri S, Wolf PA, Beiser A, et al. Stroke risk profile, brain volume, and cognitive function: the Framingham Offspring Study. Neurology. 2004;63:1591-1599.
33. Vermeer SE, Den Heijer T, Koudstaal PJ, et al. Incidence and risk factors of silent brain infarcts in the population-based Rotterdam Scan Study. Stroke. 2003;34:392-396.
34. Lopez OL, Jagust WJ, Dulberg C, et al. Risk factors for mild cognitive impairment in the cardiovascular health study cognition study: part 2. Arch Neurol. 2003;60:1394-1399.
35. DeCarli C. The role of cerebrovascular disease in dementia. Neurologist. 2003;9:123-136.
36. Schneider JA, Wilson RS, Bienias JL, et al. Cerebral infarctions and the likelihood of dementia from Alzheimer disease pathology. Neurology. 2004;62:1148-1155.
37. Schneider JA, Wilson RS, Cochran EJ, et al. Relation of cerebral infarctions to dementia and cognitive function in older persons. Neurology. 2003;60:1082-1088.
38. Jeerakathil T, Wolf PA, Beiser A, et al. Stroke risk profile predicts white matter hyperintensity volume: the Framingham Study. Stroke. 2004;35:1857-1861.
39. Gottesman II, Gould TD. The endophenotype concept in psychiatry: etymology and strategic intentions. Am J Psychiatry. 2003;160:636-645.
40. T.Cuenco K, Green RC, Zhang J, et al, for the MIRAGE Study Group. Magnetic resonance imaging traits in siblings discordant for Alzheimer disease. J Neuroimaging. In press.
41. Carmelli D, Swan GE, DeCarli C, et al. Quantitative genetic modeling of regional brain volumes and cognitive performance in older male twins. Biol Psychol. 2002;61:139-155.
42. Sullivan EV, Pfefferbaum A, Swan GE, et al. Heritability of hippocampal size in elderly twin men: equivalent influence from genes and environment. Hippocampus. 2001;11:754-762.
43. Carmelli D, DeCarli C, Swan GE, et al. Evidence for genetic variance in white matter hyperintensity volume in normal elderly male twins. Stroke. 1998;29:1177-1181.
44. Thompson PM, Cannon TD, Narr KL, et al. Genetic influences on brain structure. Nat Neurosci. 2001;4:1253-1258.
45. Turner ST, Fornage M, Jack CR Jr, et al. Genomic susceptibility loci for brain atrophy in hypertensive sibships from the GENOA study. Hypertension. 2005;45:793-798.
46. Turner ST, Jack CR, Fornage M, et al. Heritability of leukoaraiosis in hypertensive sibships. Hypertension. 2004;43:483-487.
47. Atwood LD, Wolf PA, Heard-Costa NL, et al. Genetic variation in white matter hyperintensity volume in the Framingham Study. Stroke. 2004;35:1609-1613.
48. Demissie S, Green RC, Mucci L, et al. Reliability of information collected by proxy in family studies of Alzheimer's disease. Neuroepidemiology. 2001;20:105-111.
49. Farrer LA, Cupples LA, Blackburn S, et al. Interrater agreement for diagnosis of Alzheimer's disease: the MIRAGE study. Neurology. 1994;44:652-656.
50. Lautenschlager NT, Cupples LA, Rao VS, et al. Risk of dementia among relatives of Alzheimer's disease patients in the MIRAGE study: what is in store for the oldest old? Neurology. 1996;46:641-650.
51. McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984;34:939-944.
52. Roccaforte WH, Burke WJ, Bayer BL, et al. Validation of a telephone version of the mini-mental state examination. J Am Geriatr Soc. 1992;40:697-702.
53. Scheltens P, Leys D, Barkhof F, et al. Atrophy of medial temporal lobes on MRI in "probable" Alzheimer's disease and normal ageing: diagnostic value and neuropsychological correlates. J Neurol Neurosurg Psychiatry. 1992;55:967-972.
54. Scheltens P, Launer LJ, Barkhof F, et al. Visual assessment of medial temporal lobe atrophy on magnetic resonance imaging: interobserver reliability. J Neurol. 1995;242:557-560.
55. Scheltens P, Pasquier F, Weerts JG, et al. Qualitative assessment of cerebral atrophy on MRI: inter- and intra-observer reproducibility in dementia and normal aging. Eur Neurol. 1997;37:95-99.
56. Almasy L, Blangero J. Multipoint quantitative-trait linkage analysis in general pedigrees. Am J Hum Genet. 1998;62:1198-1211.
57. Green RC, Cupples LA, Go R, et al. Risk of dementia among white and African American relatives of patients with Alzheimer disease. JAMA. 2002;287:329-336.
58. Barber R, Gholkar A, Scheltens P, et al. Apolipoprotein E epsilon4 allele, temporal lobe atrophy, and white matter lesions in late-life dementias. Arch Neurol. 1999;56:961-965.
59. Hirono N, Kitagaki H, Kazui H, et al. Impact of white matter changes on clinical manifestation of Alzheimer's disease: a quantitative study. Stroke. 2000;31:2182-2188.
60. DeCarli C, Reed T, Miller BL, et al. Impact of apolipoprotein E epsilon4 and vascular disease on brain morphology in men from the NHLBI twin study. Stroke. 1999;30:1548-1553.
61. Schmidt R, Schmidt H, Fazekas F, et al. Apolipoprotein E polymorphism and silent microangiopathy-related cerebral damage. Results of the Austrian Stroke Prevention Study. Stroke. 1997;28:951-956.
62. Tang MX, Maestre G, Tsai WY, et al. Relative risk of Alzheimer disease and age-at-onset distributions, based on APOE genotypes among elderly African Americans, Caucasians, and Hispanics in New York City. Am J Hum Genet. 1996;58:574-584.
63. Jack CR Jr, Petersen RC, Xu YC, et al. Hippocampal atrophy and apolipoprotein E genotype are independently associated with Alzheimer's disease. Ann Neurol. 1998;43:303-310.